Cruz-Guerrero RF, Jiménez-Ávila JM, González-Cisneros AC, Rivera-Villa AH, Sánchez-Chávez FA, Rincón-Gómez MR, Morales-De los Santos R, Rivera-Villa ÁO, Pérez-Atanasio JM

Idioma: Español
Referencias bibliográficas: 33
Paginas: 164-169
Archivo PDF: 235.65 Kb.

RESUMEN

Objetivo: Determinar si el uso de almidón en la artroplastia de cadera es un factor de riesgo para el sangrado transquirúrgico excesivo y el uso de concentrados eritrocitarios. Método: Estudio retrospectivo observacional analítico de 240 pacientes sometidos a artroplastia total de cadera primaria desde enero de 2015 hasta enero de 2016. Se integraron dos grupos: almidón (94 pacientes) y no almidón (146 pacientes). Se analizaron la edad, el sexo, el índice de masa corporal, la hemoglobina prequirúrgica y posquirúrgica, el uso de concentrados eritrocitarios y el sangrado transquirúrgico. Resultados: El grupo con almidón tuvo mayor riesgo de sangrado transquirúrgico excesivo (odds ratio [OR]: 3.58; intervalo de confianza del 95% [IC 95%]: 2.05- 6.26) y de transfusión de concentrados eritrocitarios (OR: 3.12; IC 95%: 1.76-5.5). En el grupo con almidón hubo una media de sangrado transquirúrgico de 396 ml (desviación estándar [DE]: ± 234.94) y una disminución de la hemoglobina de 4.6 g/dl (DE: ± 1.38); en el grupo de no almidón hubo una media de sangrado de 271.8 ml (DE: ± 139.22) y una disminución de la hemoglobina de 3.34 g/dl (DE: ± 1.4). Discusión: Los pacientes con almidón presentaron mayor sangrado transquirúrgico y requirieron en más ocasiones la transfusión de hemoderivados que los del grupo control, por lo que sugerimos considerar las posibles complicaciones relacionadas con el uso de hidroxietilalmidón.

REFERENCIAS (EN ESTE ARTÍCULO)

1. Keating EM, Pickering TR. Blood management. En: Berry DJ, Lieberman JR, editores. Surgery of the hip. Philadelphia: Elsevier Saunders. 2012;2:295-300.

2. Nuttall GA, Santrach PJ, Oliver WC, Horlocker TT, Cabanela ME. The predictors of red cell transfusions in total hip arthroplasties. Transfusion. 1996;36:144-9.

3. Harwin SF, Issa K, Naziri Q, Johnson AJ, Mont MA. Results of primary total knee arthroplasty in Jehovah’s Witness patients. J Arthroplast. 2013;28:49-55.

4. Flordal PA, Neander G. Blood loss in total hip replacement. Arch Orthop Trauma Surg. 1991;111:34-8.

5. Keating EM, Ritter MA. Transfusion options in total joint arthroplasty. J Arthroplasty. 2002;17(4 Suppl 1):125-8.

6. Keating EM, Meding JB. Perioperative blood management practices in elective orthopaedic surgery. J Am Acad Orthop Surg. 2002;10:393-400.

7. Park JH, Rasouli MR, Mortazavi SMJ, Tokarski AT, Maltenfort MG, Parvizi J. Predictors of perioperative blood loss in total joint arthroplasty. J Bone Joint Surg Am. 2013;95:1777-83.

8. Salido JA, Marín LA, Gómez LA, Zorrilla P, Martínez C. Preoperative hemoglobin levels and the need for transfusion after prosthetic hip and knee surgery: analysis of predictive factors. J Bone Joint Surg Am. 2002;84-A:216-20.

9. Carling MS, Jeppsson A, Eriksson BI, Brisby H. Transfusions and blood loss in total hip and knee arthroplasty: a prospective observational study. J Orthop Surg Rest. 2015;10:48.

10. Hatzidakis AM, Mendlick RM, McKillip T, Reddy RL, Garvin KL. Preoperative autologous donation for total joint arthroplasty. An analysis of risk factors for allogenic transfusion. J Bone Joint Surg Am. 2000;82:89-100.

11. Guerin S, Collins C, Kapoor H, McClean I, Collins D. Blood transfusion requirement prediction in patients undergoing primary total hip and knee arthroplasty. Transfus Med. 2007;17:37-43.

12. Aderinto J, Brenkel IJ. Pre-operative predictors of the requirement for blood transfusion following total hip replacement. J Bone Jt Surg. 2004;86:970-3.

13. Pola E, Papaleo P, Santoliquido A, Gasparini G, Aulisa L, De Santis E. Clinical factors associated with an increased risk of perioperative blood transfusion in nonanemic patients undergoing total hip arthroplasty. J Bone Joint Surg Am. 2004;86-A 57-61.

14. Sizer SC, Cherian JJ, Elmallah RD, Pierce TP, Beaver WB, Mont MA. Predicting blood loss in total knee and hip arthroplasty. Orthop Clin North Am. 2015;46:445-59.

15. Hrnack SA, Skeen N, Xu T, Rosenstein AD. Correlation of body mass index and blood loss during total knee and total hip arthroplasty. Am J Orthop (Belle Mead NJ). 2012;41:467-71.

16. Keith I. Anaesthesia and blood loss in total hip replacement. Anaesthesia. 1977;32:444-50.

17. Patel A, Laffan MA, Waheed U, Brett SJ. Randomised trials of human albumin for adults with sepsis: systematic review and meta-analysis with trial sequential analysis of all-cause mortality. BMJ. 2014;349 g4561.

18. US Food and Drug Administration. Hydroxyethyl starch solutions: FDA safety communication — boxed warning on increased mortality and severe renal injury and risk of bleeding. 2013. el link no funciona Disponible en: www.medicinesresources nhs uk/en/Medicines-Awareness/Safety- Alerts/Safety-alerts/Hydroxyethyl-Starch-Solutions-FDA-Safety- Communication---Boxed-Warning-on-Increased-Mortality-and-Severe- Renal-Injury-and-Risk-of-Bleeding/

19. European Medicines Agency. PRAC confirms that hydroxyethyl-starch solutions (HES) should no longer be used in patients with sepsis or burn injuries or in critically ill patients. European Medicines Agency. 2013;44:20-1.

20. Innerhofer P, Fries D, Margreiter J, Klingler A, Kühbacher G, Wachter B, et al. The effects of perioperatively administered colloids and crystalloids on primary platelet-mediated hemostasis and clot formation. Anesth Analg. 2002;95:858-65.

21. Rasmussen KC, Johansson PI, Højskov M, Kridina I, Kistorp T, Thind P, et al. Hydroxyethyl starch reduces coagulation competence and increases blood loss during major surgery: results from a randomized controlled trial. Ann Surg. 2014;259:249-54.

22. Schramko A, Suojaranta-Ylinen R, Kuitunen A, Raivio P, Kukkonen S, Niemi T. Hydroxyethylstarch and gelatin solutions impair blood coagulation after cardiac surgery: a prospective randomized trial. Br J Anaesth. 2010;104 691-7.

23. Wiedermann CJ, Joannidis M. Accumulation of hydroxyethyl starch in human and animal tissues: a systematic review. Intensive Care Med. 2014;40:160-70.

24. Haase N, Perner A, Hennings LI, Siegemund M, Lauridsen B, Wetterslev M, et al. Hydroxyethyl starch 130/0 38-0.45 versus crystalloid or albumin in patients with sepsis: systematic review with meta-analysis and trial sequential analysis. BMJ. 2013;346:f839.

25. Brunkhorst FM, Engel C, Bloos F, Meier-Hellmann A, Ragaller M, Weiler N, et al. Intensive insulin therapy and pentastarch resuscitation in severe sepsis. N Engl J Med. 2008;358:125-39.

26. Taylor M, Bromilow J. Hydroxyethyl starch 130/0.42 versus Ringer’s acetate in severe sepsis. J Intensive Care Soc. 2013;14:82-3.

27. Zarychanski R, Abou-Setta A. Association of hydroxyethyl starch administration with mortality and acute kidney injury in critically ill patients requiring volume resuscitation: a systematic review and. JAMA. 2013;309: 678-88.

28. Zdolsek HJ, Vegfors M, Lindahl TL, Törnquist T, Bortnik P, Hahn RG. Hydroxyethyl starches and dextran during hip replacement surgery: effects on blood volume and coagulation. Acta Anaesthesiol Scand. 2011;55:677-85.

29. Gandhi SD, Weiskopf RB, Jungheinrich C, Koorn R, Miller D, Shangraw RE, et al. Volume replacement therapy during major orthopedic surgery using Voluven® (hydroxyethyl starch 130/0.4) or hetastarch. Anesthesiology. 2007;106:1120-7.

30. Wise J. Boldt: the great pretender. BMJ. 2013;346:f1738.

31. Hamaji A, Hajjar L, Caiero M, Almeida J, Nakamura RE, Osawa EA, et al. Volume replacement therapy during hip arthroplasty to lactated Ringer decreases allogeneic blood transfusion and postoperative infection. Brazilian J Anesthesiol. 2013;63:27-44.

32. Opperer M, Poeran J, Rasul R, Mazumdar M, Memtsoudis SG. Use of perioperative hydroxyethyl starch 6% and albumin 5% in elective joint arthroplasty and association with adverse outcomes: a retrospective population based analysis. BMJ. 2015;350:h1567.

33. Ponnusamy KE, Kim TJ, Khanuja HS. Perioperative blood transfusions in orthopaedic surgery. J Bone Joint Surg Am. 2014;96:1836-44.